All patients with CAP should have their blood oxygen monitored with pulse oximetry. In some cases, arterial blood gas analysis may be required to determine the amount of oxygen in the blood. A complete blood count (CBC) may reveal extra white blood cells, indicating infection. Prevention
CAP may be prevented by treating underlying illnesses that increasing its risk, by smoking cessation, and by vaccination. Vaccination against haemophilus influenzae and streptococcus pneumoniae in the first year of life has been protective against childhood CAP. A vaccine against streptococcus pneumoniae, available for adults, is recommended for healthy individuals over 65 and all adults with COPD, heart failure, diabetes mellitus, cirrhosis, alcoholism, cerebrospinal fluid leaks or who have had a splenectomy. Re-vaccination may be required after five or ten years.Patients who have been vaccinated against streptococcus pneumoniae, health professionals, nursing-home residents and pregnant women should be vaccinated annually against influenza. During an outbreak, drugs such as amantadine, rimantadine, zanamivir and oseltamivir have been demonstrated to prevent influenza. Treatment
CAP is treated with an antibiotic that kills the infecting microorganism; treatment also aims at managing complications. If the causative microorganism is unidentified, which is often the case, the laboratory identifies the most effective antibiotic; this may take several days. Health professionals consider a persons risk factors for various organisms when choosing an initial antibiotic. Additional consideration is given to the treatment setting; most patients are cured by oral medication, while others must be hospitalized for intravenous therapy or intensive care.
Rolaids is an American brand of calcium and magnesium-based antacid produced by Chattem. It was invented by American chemist Irvine W. Grote in the late 1920s, and originated with manufacturing in Chattanooga, Tennessee, under one of Chattems forerunner companies, which manufactured the brand for Warner-Lambert; Warner-Lambert merged with Pfizer in 2000. In 2006, McNeil Consumer Healthcare, a subsidiary of Johnson & Johnson, acquired the brand from Pfizer Consumer Healthcare. In 2013, McNeil sold the brand to Sanofi, following a two-year period where the brand was pulled off the market due to product recalls resulting from quality control and manufacturing issues that also left former fellow antacid brand Pepcid ACs "chewables" product and other fellow McNeil products like some varieties of Tylenol off store shelves for the same period. Rolaids returned to the market at the beginning of September 2013 under Chattem ownership with new packaging, trade dress, and a new liquid variety. Rolaids tablets come in many different flavors, including original peppermint, cherry, freshmint, fruit, tropical, punch, cool mint, berry, and apple. 2010 recall
McNeil Consumer Healthcare voluntarily recalled Rolaids products in the Americas, the United Arab Emirates (UAE), and Fiji on January 15, 2010, in consultation with the FDA. The company initiated the recall following an investigation of consumer reports of an unusual moldy, musty, or mildewlike odor that, in a small number of cases, was associated with temporary and nonserious gastrointestinal events. These events included nausea, stomach pain, vomiting, and diarrhea.